OKYO Pharma Limited

NASDAQ:OKYO

Biotechnology

Healthcare
$1.10 +0.64%

+$0.01 today

Market cap
$57.73M
Beta
0.02
P/E (TTM)
-12.8
EPS (TTM)
-$0.12
52W Low $1.42High $3.35

Volume 0.24M

Average 0.07M

OKYO Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

OKYO Pharma LimitedNASDAQ: OKYO

Retained Earnings · Q2 FY2026 · quarter ended Sep 2025

Retained earnings remains negative

Q2 FY2026 retained earnings was -$145.61M, compared with -$145.2M a year earlier.

Context

  • Retained earnings amounted to 3135.5% of total assets at the end of Q2 FY2026, down 1997.4 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -0.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2025
-$145.61M— QoQ
Last fiscal yearMar 2025
-$143.02M-0.4% YoY
Year agoSep 2024
-$145.2M-0.3% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.3%——
1 year-0.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(143.02M) USD
Year-over-year change
-0.4%

Retained Earnings vs competitors

How OKYO compares with its peers on the latest reported figures

  • OKYO's Sep 2025 retained earnings of -$145.61M is the 4th highest of the 10 companies compared; the peer median is -$316.39M.
  • Its year-over-year change of -0.3% is the 2nd highest of 10, against a peer median of -11.8%.
  • Retained earnings amounts to 3135.5% of total assets for OKYO, versus a peer median of 411.2%.
OKYO Competitors Peer median
Retained Earnings for OKYO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TLSATiziana Life Sciences LtdDec 2025-$44.41M +69.3%—386.4%
COYACoya Therapeutics, Inc.Mar 2026-$69.17M -44.0%—129.8%
IMMXImmix Biopharma, Inc.Mar 2026-$114.55M -44.0%—119.6%
OKYOOKYO Pharma LimitedSep 2025-$145.61M -0.3%—3135.5%
SLGLSol-Gel Technologies Ltd.Mar 2026-$240.74M -0.4%—411.2%
CLNNClene Inc.Mar 2026-$316.39M -11.8%—1460.4%
WHWKWhitehawk Therapeutics IncMar 2026-$375.44M -44.6%—295.1%
PLRXPliant Therapeutics, Inc.Mar 2026-$879.44M -14.8%—434.1%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026-$1.23B -11.3%—484.8%
MGNXMacroGenics, Inc.Mar 2026-$1.28B -5.8%—588.0%
Peer median (excluding OKYO) -$316.39M-11.8%—411.2%

Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Cash & Equivalents6.89M2.7M4.05M826.85K1.56M
Short-term Investments00000
Net Receivables4.5K883.44K980.08K580.94K1.89M
Inventory34(1.49K)170.31K00
Other Current Assets71.75K1.49K(170.31K)00
Total Current Assets6.99M4.3M5.2M1.54M3.68M
Property, Plant & Equipment (Net)104.64K5.23K7.22K3.35K2.04K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets104.64K5.23K7.22K3.35K2.04K
Total Assets7.09M4.3M5.2M1.54M3.68M
Account Payables210.99K517.67K1.02M6.13M7.9M
Short-term Debt34.14K02.22M00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.43M323.06K1.29M7.1M9.04M
Total Current Liabilities1.71M1.35M7.26M7.42M9.23M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities64.61K0000
Total Liabilities1.77M1.35M7.26M7.42M9.23M
Common Stock0123.98M0143.11M0
Retained Earnings(99.4M)(112.43M)(125.7M)(142.52M)(143.02M)
Accumulated OCI12.82M(11.01M)(7.74M)(11.31M)(11.47M)
Other Stockholders Equity(1)2.41M1734.84M2.23M
Minority Interest00000
Total Equity5.32M2.95M(2.05M)(5.88M)(5.55M)
Total Debt98.76K02.22M00
Net Debt(6.79M)(2.7M)(1.83M)(826.85K)(1.56M)

OKYO Pharma Limited

NASDAQ:OKYO

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.